Stabilizing versus Destabilizing the Microtubules: A Double-Edge Sword for an Effective Cancer Treatment Option?

Romidepsin in peripheral and cutaneous T-cell lymphoma: mechanistic implications from clinical and correlative data

(2015) Susan E. Bates et al.   BRITISH JOURNAL OF HAEMATOLOGY

Mitosis, microtubule dynamics and the evolution of kinesins

(2015) Juan Jesus Vicente et al.   EXPERIMENTAL CELL RESEARCH

Ombrabulin plus cisplatin versus placebo plus cisplatin in patients with advanced soft-tissue sarcomas after failure of anthracycline and ifosfamide chemotherapy: a randomised, double-blind, placebo-controlled, phase 3 trial

(2015) Jean-Yves Blay et al.   LANCET ONCOLOGY

Drug-Resistant Urothelial Cancer Cell Lines Display Diverse Sensitivity Profiles to Potential Second-Line Therapeutics

(2015) Stefan Vallo et al.   Translational Oncology

Designing and Testing of Novel Taxanes to Probe the Highly Complex Mechanisms by Which Taxanes Bind to Microtubules and Cause Cytotoxicity to Cancer Cells

(2015) Marc St. George et al.   PLoS One

Structural Basis of Microtubule Stabilization by Laulimalide and Peloruside A

(2014) Andrea E. Prota et al.   ANGEWANDTE CHEMIE-INTERNATIONAL EDITION

Microtubule-targeting Anticancer Agents from Marine Natural Substance

(2014) Zhiguo Liu et al.   Anti-Cancer Agents in Medicinal Chemistry

Development of other microtubule-stabilizer families

(2014) Cynthia F. Brogdon et al.   ANTI-CANCER DRUGS

Microtubule-targeting agents are clinically successful due to both mitotic and interphase impairment of microtubule function

(2014) Jessica J. Field et al.   BIOORGANIC & MEDICINAL CHEMISTRY

Pseudolaric Acid B Circumvents Multidrug Resistance Phenotype in Human Gastric Cancer SGC7901/ADR Cells by Downregulating Cox-2 and P-gp Expression

(2014) Fei Yu et al.   CELL BIOCHEMISTRY AND BIOPHYSICS

The Unique Binding Mode of Laulimalide to Two Tubulin Protofilaments

(2014) Cassandra D. M. Churchill et al.   Chemical Biology & Drug Design

Retracted: Synthesis and Cytotoxic Activity of 2-Anilinopyridine-3-Acrylamides as Tubulin Polymerization Inhibitors

(2014) Ahmed Kamal et al.   ChemMedChem

Fosbretabulin for the treatment of anaplastic thyroid cancer

(2014) Roberta Granata et al.   Future Oncology

Design, Synthesis, and Biological Evaluation of Novel Pyridine-Bridged Analogues of Combretastatin-A4 as Anticancer Agents

(2014) Shilong Zheng et al.   JOURNAL OF MEDICINAL CHEMISTRY

Targeting Microtubules by Natural Agents for Cancer Therapy

(2014) E. Mukhtar et al.   MOLECULAR CANCER THERAPEUTICS

The Inhibitory Effect of Pseudolaric Acid B on Gastric Cancer and Multidrug Resistance via Cox-2/PKC-α/P-gp Pathway

(2014) Qian Sun et al.   PLoS One

A new tubulin-binding site and pharmacophore for microtubule-destabilizing anticancer drugs

(2014) A. E. Prota et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Microtubule inhibitor-based antibody–drug conjugates for cancer therapy

(2014) Scott Tagawa et al.   OncoTargets and Therapy

Microtubule-targeting agents in oncology and therapeutic potential in hepatocellular carcinoma

(2014) Winnie Yeo et al.   OncoTargets and Therapy

Microtubules and Their Role in Cellular Stress in Cancer

(2014) Amelia L. Parker et al.   Frontiers in Oncology

Vascular-disrupting agents in oncology

(2013) Monica M Mita et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Tubulin inhibitors: a patent review

(2013) Yi-Min Liu et al.   EXPERT OPINION ON THERAPEUTIC PATENTS

Recent approaches for the synthesis of modified cryptophycins

(2013) Christine Weiss et al.   NATURAL PRODUCT REPORTS

Randomized Safety and Efficacy Study of Fosbretabulin with Paclitaxel/Carboplatin Against Anaplastic Thyroid Carcinoma

(2013) Julie A. Sosa et al.   THYROID

MT-Stabilizer, Dictyostatin, Exhibits Prolonged Brain Retention and Activity: Potential Therapeutic Implications

(2013) Kurt R. Brunden et al.   ACS Medicinal Chemistry Letters

Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial

(2012) J Cummings et al.   BRITISH JOURNAL OF CANCER

Discovery of Small Molecule Inhibitors that Interact with γ-Tubulin

(2012) Douglas E. Friesen et al.   Chemical Biology & Drug Design

Efficient, divergent synthesis of cryptophycin unit A analogues

(2012) Kyle L. Bolduc et al.   CHEMICAL COMMUNICATIONS

A Phase I Trial and in vitro Studies Combining ABT-751 with Carboplatin in Previously Treated Non-Small Cell Lung Cancer Patients

(2012) Tian Ma et al.   CHEMOTHERAPY

Phase I Clinical and Pharmacokinetic Evaluation of the Vascular-Disrupting Agent OXi4503 in Patients with Advanced Solid Tumors

(2012) Dan M. Patterson et al.   CLINICAL CANCER RESEARCH

The Vascular-Disrupting Agent Combretastatin Impairs Splitting and Sprouting Forms of Physiological Angiogenesis

(2012) ARIF HUSSAIN et al.   MICROCIRCULATION

Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer

(2011) Marta De Donato et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Phase I/II Study of Pemetrexed With or Without ABT-751 in Advanced or Metastatic Non–Small-Cell Lung Cancer

(2011) Charles M. Rudin et al.   JOURNAL OF CLINICAL ONCOLOGY

A Simplified Synthesis of Novel Dictyostatin Analogues with In Vitro Activity against Epothilone B-Resistant Cells and Antiangiogenic Activity in Zebrafish Embryos

(2011) L. L. Vollmer et al.   MOLECULAR CANCER THERAPEUTICS

βIII-Tubulin Is a Multifunctional Protein Involved in Drug Sensitivity and Tumorigenesis in Non–Small Cell Lung Cancer

(2010) Joshua A. McCarroll et al.   CANCER RESEARCH

Differential expression and cellular distribution of γ-tubulin and βIII-tubulin in medulloblastomas and human medulloblastoma cell lines

(2010) Valentina Caracciolo et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Microtubule Dynamics, Mitotic Arrest, and Apoptosis: Drug-Induced Differential Effects of  III-Tubulin

(2010) P. P. Gan et al.   MOLECULAR CANCER THERAPEUTICS

Microtubule-binding agents: a dynamic field of cancer therapeutics

(2010) Charles Dumontet et al.   NATURE REVIEWS DRUG DISCOVERY

Increased  -tubulin expression and P16INK4A promoter methylation occur together in preinvasive lesions and carcinomas of the breast

(2009) T. Liu et al.   ANNALS OF ONCOLOGY

A phase IB study of ABT-751 in combination with docetaxel in patients with advanced castration-resistant prostate cancer

(2009) J. Michels et al.   ANNALS OF ONCOLOGY

A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P)

(2009) Dietmar W Siemann et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

AVE8062: a new combretastatin derivative vascular disrupting agent

(2009) Angelo Delmonte et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Phase II Multi-Institutional Trial of the Histone Deacetylase Inhibitor Romidepsin As Monotherapy for Patients With Cutaneous T-Cell Lymphoma

(2009) Richard L. Piekarz et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase II Clinical Trial of Ixabepilone in Patients With Recurrent or Persistent Platinum- and Taxane-Resistant Ovarian or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study

(2009) Koen De Geest et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer

(2008) J. Horti et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Indibulin, a Novel Microtubule Inhibitor, Discriminates between Mature Neuronal and Nonneuronal Tubulin

(2008) A. Wienecke et al.   CANCER RESEARCH

Microtubule dynamics as a target in oncology

(2008) April L. Risinger et al.   CANCER TREATMENT REVIEWS

A Phase I Study of ABT-751, an Orally Bioavailable Tubulin Inhibitor, Administered Daily for 21 Days Every 28 Days in Pediatric Patients with Solid Tumors

(2008) E. Fox et al.   CLINICAL CANCER RESEARCH

Phase II Trial of T138067, a Novel Microtubule Inhibitor, in Patients with Metastatic, Refractory Colorectal Carcinoma

(2008) Jordan D. Berlin et al.   Clinical Colorectal Cancer

A Phase II Study of ABT-751 in Patients with Advanced Non-small Cell Lung Cancer

(2008) Ann M. Mauer et al.   Journal of Thoracic Oncology

Ixabepilone: A Novel Antineoplastic Agent with Low Susceptibility to Multiple Tumor Resistance Mechanisms

(2008) L. Vahdat   ONCOLOGIST

Hypoxia induces class III beta-tubulin gene expression by HIF-1α binding to its 3' flanking region

(2007) Giuseppina Raspaglio et al.   GENE